146 related articles for article (PubMed ID: 11878777)
1. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
2. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
3. Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression.
Anderson CP; Keshelava N; Satake N; Meek WH; Reynolds CP
Med Pediatr Oncol; 2000 Dec; 35(6):659-62. PubMed ID: 11107141
[TBL] [Abstract][Full Text] [Related]
4. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
[TBL] [Abstract][Full Text] [Related]
5. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma.
Villablanca JG; Volchenboum SL; Cho H; Kang MH; Cohn SL; Anderson CP; Marachelian A; Groshen S; Tsao-Wei D; Matthay KK; Maris JM; Hasenauer CE; Czarnecki S; Lai H; Goodarzian F; Shimada H; Reynolds CP
Pediatr Blood Cancer; 2016 Aug; 63(8):1349-56. PubMed ID: 27092812
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Bailey HH; Mulcahy RT; Tutsch KD; Arzoomanian RZ; Alberti D; Tombes MB; Wilding G; Pomplun M; Spriggs DR
J Clin Oncol; 1994 Jan; 12(1):194-205. PubMed ID: 8270977
[TBL] [Abstract][Full Text] [Related]
7. Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.
Anderson CP; Matthay KK; Perentesis JP; Neglia JP; Bailey HH; Villablanca JG; Groshen S; Hasenauer B; Maris JM; Seeger RC; Reynolds CP
Pediatr Blood Cancer; 2015 Oct; 62(10):1739-46. PubMed ID: 26153194
[TBL] [Abstract][Full Text] [Related]
8. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis.
Anderson CP; Tsai JM; Meek WE; Liu RM; Tang Y; Forman HJ; Reynolds CP
Exp Cell Res; 1999 Jan; 246(1):183-92. PubMed ID: 9882527
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
O'Dwyer PJ; Hamilton TC; LaCreta FP; Gallo JM; Kilpatrick D; Halbherr T; Brennan J; Bookman MA; Hoffman J; Young RC; Comis RL; Ozols RF
J Clin Oncol; 1996 Jan; 14(1):249-56. PubMed ID: 8558205
[TBL] [Abstract][Full Text] [Related]
10. The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.
Tagde A; Singh H; Kang MH; Reynolds CP
Blood Cancer J; 2014 Jul; 4(7):e229. PubMed ID: 25036800
[TBL] [Abstract][Full Text] [Related]
11. Effect of glutathione depletion on inhibition of cell cycle progression and induction of apoptosis by melphalan (L-phenylalanine mustard) in human colorectal cancer cells.
Vahrmeijer AL; van Dierendonck JH; Schutrups J; van de Velde CJ; Mulder GJ
Biochem Pharmacol; 1999 Aug; 58(4):655-64. PubMed ID: 10413303
[TBL] [Abstract][Full Text] [Related]
12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.
Bailey HH; Ripple G; Tutsch KD; Arzoomanian RZ; Alberti D; Feierabend C; Mahvi D; Schink J; Pomplun M; Mulcahy RT; Wilding G
J Natl Cancer Inst; 1997 Dec; 89(23):1789-96. PubMed ID: 9392620
[TBL] [Abstract][Full Text] [Related]
15. L-S,R-buthionine sulfoximine: historical development and clinical issues.
Bailey HH
Chem Biol Interact; 1998 Apr; 111-112():239-54. PubMed ID: 9679558
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of melphalan activity by buthionine sulfoximine and electroporation in melanoma cells.
Ongaro A; Pellati A; De Mattei M; De Terlizzi F; Rossi CR; Campana LG
Anticancer Drugs; 2015 Mar; 26(3):284-92. PubMed ID: 25514113
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of buthionine sulfoximine cytotoxicity for human neuroblastoma cell lines by hypoxia is reversed by the bioreductive agent tirapazamine.
Yang B; Keshelava N; Anderson CP; Reynolds CP
Cancer Res; 2003 Apr; 63(7):1520-6. PubMed ID: 12670899
[TBL] [Abstract][Full Text] [Related]
18. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
19. Effects of buthionine sulfoximine treatment on cellular glutathione levels and cytotoxicities of cisplatin, carboplatin and radiation in human stomach and ovarian cancer cell lines.
Lee KS; Kim HK; Moon HS; Hong YS; Kang JH; Kim DJ; Park JG
Korean J Intern Med; 1992 Jul; 7(2):111-7. PubMed ID: 1306072
[TBL] [Abstract][Full Text] [Related]
20. [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
Wang T; Ma LM; Zhang HP; Wang HW; Yang LH; Qiao ZH
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):188-91. PubMed ID: 18756933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
